Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person15
Fastly, Inc.
Company
F5, INC.
Company
Farmmi, Inc.
Company
FiEE, Inc.
Company
MEDIFAST INC
Company
Firy Inc.
Company
FIGS, Inc.
Company
Fabric.AI, Inc.
Company
Fermi Inc.
Company
Toast, Inc.
Company
Figma, Inc.
Company
Five9, Inc.
Company
Funko, Inc.
Company
Family Trading Inc.
Company
Fatpipe Inc/UT
Company
Primary record15
FMR LLC filed SCHEDULE 13G/A
0000315066-26-002753.txt : 20261105 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0000315066-26-001193 0000315066 XXXXXXXX LIVE 2 CLASS A COMMON STOCK 09/30/2026 0001517413 FASTLY INC 31188V100 475 BRANNAN, SUITE
Fastly, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of President, Go to Market On October 30, 2026, Sco
Fastly, Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Fastly, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026 by issuing a press release. A copy of th
Fastly, Inc. filed SCHEDULE 13G/A
0002100121-26-001053.txt : 20261030 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0002100121 XXXXXXXX LIVE 1 Common Stock 09/30/2026 0001517413 Fastly Inc 31188V100 475 Brannan Street Suite 300 San Francisco CA 9
New Fortress Energy Inc. filed 8-K
Item 7.01. Regulation FD Disclosure. On October 29, 2026, New Fortress Energy Inc. (“NFE” or the “Company”) issued a press release announcing that it has agreed to lease ten mobile turbines that can generate up to 300 me
Fastly, Inc. filed 4
SEC form 4 filed by Fastly, Inc. (CIK 1517413) on 2026-10-28.
Fastly, Inc. filed 4
SEC form 4 filed by Fastly, Inc. (CIK 1517413) on 2026-10-28.
CUMBERLAND PHARMACEUTICALS INC filed 8-K
Item 7.01 Regulation FD Disclosure. On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued
Fastly, Inc. filed 4
SEC form 4 filed by Fastly, Inc. (CIK 1517413) on 2026-10-20.
Coya Therapeutics, Inc. filed 8-K
Item 8.01 Other Events. On October 14, 2026, Coya Therapeutics, Inc. (the Company ) issued a press release announcing plans to initiate an open-label extension ( OLE ) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluat
Fastly, Inc. filed 4
SEC form 4 filed by Fastly, Inc. (CIK 1517413) on 2026-10-14.
SAB Biotherapeutics, Inc. filed 8-K
Item 8.01 Other Events. On October 13, 2026, SAB Biotherapeutics, Inc., a Delaware corporation, issued a press release (the Release ) announcing that the U.S. Food and Drug Administration has granted Fast Track designati
Perspective Therapeutics, Inc. filed 8-K
Item 8.01 Other Events. On October 8, 2026, Perspective Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for the development of PSV359 for adu
Vir Biotechnology, Inc. filed 8-K
Item 8.01 Other Events. On October 8, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track designation to VIR-5500, a PSMA-target
Coya Therapeutics, Inc. filed 8-K
Item 8.01 Other Events. On October 5, 2026, Coya Therapeutics, Inc. (the Company ) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company s ongoing Phase 2/3